Dr. Omid Hamid is an Oncology/Hematology specialist affiliated to Marina del Rey Hospital. He received his medical degree from the University of Southern California Keck School of Medicine and completed his residency at the Los Angeles County Hospital/University of Southern California Medical Center. He is certified by the American Board of Oncology and is also a member of the Cancer Institute.

Insurance Accepted

  • Aetna Choice POS II
  • Cigna
  • Great West PPO
  • First Health PPO
  • Multiplan PPO

Languages Spoken

  • English
  • Farsi
  • Spanish

Education & Training

Medical Degree

University of Southern California Keck School of Medicine


University of Southern California Medical Center


University of Southern California - LAC+USC Medical Center


University of Southern California - LAC+USC Medical Center

Publications & Media

  • An immune-active tumor microenvironment favors clinical response to ipilimumab.

  • Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.

  • Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.

  • Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.

  • Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial.

  • Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006.

  • A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma.

  • Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma.

  • Eruptive Squamous Cell Carcinomas Associated with BRAF-Inhibitor Therapy in a Patient with Metastatic Melanoma.

  • Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).

  • Mucosal melanoma

  • Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.

  • Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.

  • Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma.

  • Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.

  • Phase II study of nab-paclitaxel and bevacizumab as first-line therapy for patients with unresectable stage III and IV melanoma.